Molecular Pathogenesis of Thyroid Cancer

Figge, James; Kartel, N. A.; Yarmolinsky, Dima; Ermak, Gennady

doi:10.1007/978-1-59259-995-0_3

Cited by 4 publications

(3 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatic oncogenic mutations in signal transducers participating in the RAS/MAPK cascade, including those encoded by the RET , RAS and RAF genes, represent a common molecular event contributing to papillary thyroid carcinomas (PTC) 1–10 . At least 10 different RET gene rearrangements have been documented thus far.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)

Carta

Moretti²,

Passeri³

et al. 2005

Clinical Endocrinology

View full text Add to dashboard Cite

These data indicate that BRAF mutations are the most frequent genetic event in PTC and that RAS mutations, besides being a genetic hallmark of follicular tumours, are rare or completely absent in PTC from our area. Together, BRAF mutations and rarer RET rearrangements accounted for a genetic event in two-thirds of PTCs. This study showed a novel and presumably oncogenic mutation of BRAF, which is BRAF(V599Ins).

show abstract

mentioning

confidence: 99%

“…Point mutations affecting the HRAS , KRAS2 and NRAS also recur in PTC. Their overall prevalence is variable according to different studies, but generally lower than 20% 2 . More recently, mutations of BRAF , either point mutations 3–9 or gene rearrangements, 10 have been identified.…”

mentioning

confidence: 99%

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)

Carta

Moretti²,

Passeri³

et al. 2005

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…of papillary and follicular carcinoma. The TSH pathway, on the other hand, brings about both proliferation and cell differentiation (13).…”

Section: Discussionmentioning

confidence: 99%

Blood serum level of TSH and thyroid hormones and thyroid tissue content of iodine in rats under restricted selenium and iodine supply

Glattre¹,

Eybl²,

Kotyzová³

et al. 2009

Nor J Epidemiol

View full text Add to dashboard Cite

NORSK SAMMENDRAG128 Wistar hunrotter, 30 dager gamle, ble foret med spesialkost i fire uker pluss en forsøksperiode påmaksimalt 36 timer. Blant dyrene ble 114 forsøksdyr og 7 kontroller satt på fôr med lavt innhold avselen og jod mens 7 kontrolldyr fortsatt ble holdt på standardfôr. Etter fire uker ble seks grupperforsøksdyr gitt KI i.p. i doser fra 5 til 1000 μg I. En tredel av dyrene fra alle eksponeringsgrupper bleavlivet 18 timer etter injeksjonen, en tredel fra alle eksponeringsgrupper ble avlivet 24 timer etter injeksjonenog siste tredel ble avlivet 36 timer etter. Total T4, T3, rT3 og TSH ble bestemt i serum mensjodnivået ble bestemt som våtvektskonsentrasjonen i skjoldkjertelvevet. Ni rotter gikk tapt før forsøketkunne avsluttes. Klarest for rotter avlivet 18 timer etter jodinjeksjonen kan man se at kurven for TSH erbimodal. Man fant at jodmengder helt ned til 5-10 μg/rotte ga signifikant forhøyet TSH-nivå. Dettetilsvarer mengder som mennesker lett får i seg på daglig basis på en kost rik på sjømat. Resultatet aveksperimentet blir diskutert med bakgrunn i E.D.Williams’ 25 år gamle tese om at jod i overskudd ikosten medvirker til øket risiko for utvikling av papillært karsinom i skjoldkjertelen.

show abstract

Modern Management of Differentiated Thyroid Cancer

Cohen

Kalinyak²,

McDougall

2003

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The outcome in differentiated thyroid cancer is excellent. Simple prognostic factors, including the age of the patient at diagnosis, the size of the primary cancer, completeness of surgical excision, and the presence of distant metastases, allow the clinician to judge how a patient will do. The preferred treatment is total thyroidectomy and in selected patients radioactive iodine can be used to ablate residual thyroid or functioning metastases in lymph nodes and distant sites. The physician has two excellent methods for following the patient: the whole-body scan with radionuclides of iodine, and measurement of serum thyroglobulin. In patients with elevated thyroglobulin and negative scans with radioactive iodine, there is increasing evidence that positron emission tomography (PET) is helpful in locating the site of thyroglobulin production.

show abstract

Molecular Pathogenesis of Thyroid Cancer

Cited by 4 publications

References 194 publications

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)

Blood serum level of TSH and thyroid hormones and thyroid tissue content of iodine in rats under restricted selenium and iodine supply

Modern Management of Differentiated Thyroid Cancer

Contact Info

Product

Resources

About

Molecular Pathogenesis of Thyroid Cancer

Cited by 4 publications

References 194 publications

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins)

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins)

Blood serum level of TSH and thyroid hormones and thyroid tissue content of iodine in rats under restricted selenium and iodine supply

Modern Management of Differentiated Thyroid Cancer

Contact Info

Product

Resources

About

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF^V599Ins)